Clinical Trial Search

Primary: Correlation Between the Impulsive Choice Ratio and Baseline Impulsivity, as Measured With the Barratt Impulsiveness Scale — -0.45 Correlation coefficient — p=0.032

Primary: Report on Degree of Hearing as Measured by Pure Tone Audiogram — 5; 2; 2; 0 participants

Primary: Area Under the Curve (AUC) 0-4 Hours of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes. — 75.74 mcg*hr/mL

Primary: Change in Self-Care Inventory (SCI) Score From Baseline to 6 Months — 3.57; 3.62 score on a scale — p=0.035

Primary: Frequency of Side Effects (=Systemic Reaction, SR) During Venom Immunotherapy (VIT) — 19; 74 Participants — p=0.25

Primary: Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA) — 18.4; 9.0 Percentage of participants

Primary: Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA) — 20.3; 6.5 Percentage of subjects

Primary: Cytosponge Acceptability by Number of Participants — 46; 81; 2; 6 Participants

Primary: Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12 — 29.2; 66.7; 65.7; 72.5 percentage of participants — p=< 0.0001

Primary: Percentage Of Participants With Wider Therapeutic Window With Directional Programming (Superiority) — 185 Participants — p=<0.0001

Primary: Number of Participants With a Composite Endpoint of Stroke and Systemic Embolic Events (SEE) in Participants Who Were Administered DU-176b Compared With Placebo — 15; 44…

Primary: Apnea-Hypopnea Index (AHI) Change From Baseline as Calculated From Polysonagraphy (PSG) — 0.86; 0.97 ratio

Primary: CO-verified Smoking Status at 26 Weeks — 16.3; 12.6 percentage of participants

Primary: Progression-Free Survival (PFS), as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 10.6; 15.1 months — p=0.0224

Primary: The Number of Patch Related Serious Adverse Events. — 0 Participants